ライフサイエンスコーパス: CV

1 CV hyperpolarization accelerated the rhythm to an extent

2 CV-A6 and CV-A10 were tested positive in Chongqing, but

3 We observed higher levels of all 10 CV autoantibodies in hypertensive subjects (n = 77) comp

4 pproach allowed simultaneous detection of 10 CV autoantibodies targeting the structural myocardial pr

5 ation sequencing using a custom panel of 101 CV-associated genes.

6 atients experienced the primary outcome (136 CV events and 83 additional deaths).

7 Willebrand type C domain of Crossveinless 2 (CV-2), a BMP antagonist and member of the chordin family

8 structure of the complex of crossveinless-2 (CV-2) vWC1 and BMP-2 previously revealed one mode of the

9 I with 90% (79% CV) sensitivity and 83% (76% CV) specificity.

10 classifier for bacterial LRTI with 90% (79% CV) sensitivity and 83% (76% CV) specificity.

11 an SD of 0.17 log10 copies/ml or less and a CV of </=5.2% for each level tested.

12 says also limits the potential to identify a CV-specific autoantibody profile.

13 The results show that our model possesses a CV result (R(2) = 0.81) that reflects higher accuracy th

14 HDL-C level is unlikely to represent a CV-specific risk factor given similarities in its associ

15 w values of 0.84 or lower were found, with a CV between 1 and 2%, and an ICC of more than 0.970.

16 Coxsackievirus A16 (CV-A16), CV-A6, and enterovirus D68 (EV-D68) belong to t

17 Coxsackievirus A16 (CV-A16), CV-A6, and enterovirus D68 (EV-D68) belong to the Picorn

18 Furthermore, the CV-A16, CV-A6, and EV-D68 3C(pro) proteins all cleave transformi

19 the potential merit of targeting the CV-A16, CV-A6, and EV-D68 3C(pro) proteins as an antiviral strat

20 Here we demonstrate that the CV-A16, CV-A6, and EV-D68 3C(pro) proteins block MDA5-triggered

21 In addition, the CV-A16, CV-A6, and EV-D68 3C(pro) proteins cleave TAK1 to inhibi

22 tor (RLR) pathway was blocked by the CV-A16, CV-A6, and EV-D68 3C(pro) proteins.

23 novel antiviral strategy.IMPORTANCE CV-A16, CV-A6, and EV-D68 are emerging pathogens associated with

24 vered that the 3C(pro) proteins from CV-A16, CV-A6, and EV-D68 bind melanoma differentiation-associat

25 Coxsackievirus A24 (CV-A24) was not originally associated with human disease

26 Subsequently 292 non-EV-A71/CV-A16 HFMD confirmed cases were randomly selected in th

27 62.33% while CV-A10 had 4.79% in non-EV-A71/CV-A16 HFMD confirmed cases.

28 the incretin-based therapies have acceptable CV safety profiles for patients with T2DM.

29 remain susceptible to inherited and acquired CV disease, and may be most at risk for adverse CV outco

30 disease, and may be most at risk for adverse CV outcomes during intense physical activity.

31 e also reduced CV death and/or major adverse CV events, but did so more slowly and did not influence

32 ependent renal pathway for long-term adverse CV outcomes.

33 that circulating HFMD-associated CV-A16 and CV-A6, as well as severe respiratory disease-associated

34 that circulating HFMD-associated CV-A16 and CV-A6, as well as severe respiratory disease-associated

35 CV-A6 and CV-A10 were tested positive in Chongqing, but CV-A6 had

36 ee consecutive outbreaks to detect CV-A6 and CV-A10, using RT-PCR.

37 EV-A71 and CV-A16 infection accounted for only 36.05% (7793/21615)

38 Our results predict that the EV-A71 and CV-A16 serotypes provide a temporary immunizing effect a

39 erized by TEM, XRD, FTIR, XPS, TGA, BET, and CV using the redox couples [Fe(CN)6](-3/-4) and [Ru(NH3)

40 echanism by which blood flow mediates DA and CV morphogenesis, by regulating arterial-venous specific

41 The mutant DA and CV were abnormally connected.

42 e proper separation of the developing DA and CV.

43 s are fully characterized, including EPR and CV studies for the radicals.

44 for re-entry through a reduction in ERP and CV.

45 regarding the occurrence of 30-day MACE and CV risk profile based on information from national regis

46 wn hydrogen-bonding network between Man3 and CV-N was discovered.

47 ion between different breakfast patterns and CV risk factors and the presence, distribution, and exte

48 oblasts and periosteal dura causes skull and CV malformations, similar to humans harboring TWIST1 mut

49 The Sw and CV for ACD was 0.03 mm and 1.16%, respectively, with an

50 tomical parameter evaluated and their Sw and CV values associated (-0.220 </= r </= 0.204, p >/= 0.12

51 with separation resolution exceeding 1.0 and CVs of 8.4% for BSA-OVA and 2.4% for OVA-TI, with compar

52 we establish a new protocol for fitting any CV-PAC and demonstrate its validity with experimental re

53 nd 119 consecutive LT recipients without any CV risk factors (control group II).

54 The intra-assay and inter-assay CV values of this assay were 1.5-1.7% and 2.5-4.5%, resp

55 demonstrate that circulating HFMD-associated CV-A16 and CV-A6, as well as severe respiratory disease-

56 demonstrate that circulating HFMD-associated CV-A16 and CV-A6, as well as severe respiratory disease-

57 key regulators of cardiovascular-associated (CV) genes.

58 coating of CV was applied (known as PU-AuNPs-CV).

59 SECM-based CV is obtained under high mass-transport conditions and

60 Significantly, SECM-based CV will be useful for the in situ characterization of va

61 %) than when expressed on a leaf area basis (CV = 66%), and relationships for broadleaf and needle-le

62 ctively, indicating a good agreement between CV predictions and observations.

63 t previously observed in the complex between CV-2 vWC and BMP-2, revealing an alternative mode of int

64 he strength of the positive feedback between CV and the pattern generator circuit.SIGNIFICANCE STATEM

65 While both CV-A24 variant and nonvariant strains still circulate in

66 V-A10 were tested positive in Chongqing, but CV-A6 had greater positive rates of 62.33% while CV-A10

67 (GSSG) forms of glutathione was assessed by CV studies at physiological pH.

68 suggest how such drugs might be embraced by CV specialists to reduce CV events and mortality in thei

69 h long-term risks of adverse cardiovascular (CV) events and mortality in patients after cardiac surge

70 he gastrointestinal (GI) and cardiovascular (CV) cholinergic adverse events (AEs) previously attribut

71 n patients with diabetes and cardiovascular (CV) disease, a group common in cardiology clinics.

72 44, for age >/=70 years) and cardiovascular (CV) mortality (aHR: 2.20; 95% CI: 1.22 to 3.98, for age

73 e cardiac events (MACEs) and cardiovascular (CV) risk profile in patients with chest pain discharged

74 of COPD-, respiratory-, and cardiovascular (CV)-related hospitalizations and all-cause mortality wer

75 ation between omalizumab and cardiovascular (CV)/cerebrovascular (CBV) events in EXCELS.

76 both IMiDs and PIs can have cardiovascular (CV) sequelae, which include thromboembolic complications

77 enetic testing for heritable cardiovascular (CV) disorders is often lacking because ideal specimens (

78 Ezetimibe improves cardiovascular (CV) outcomes in patients stabilized after acute coronary

79 The role of autoimmunity in cardiovascular (CV) diseases has been increasingly recognized.

80 ms contributing to increased cardiovascular (CV) risk in PTSD will pave the way for developing interv

81 is associated with increased cardiovascular (CV) risk.

82 associated with an increased cardiovascular (CV) risk.

83 The rates of cardiovascular (CV) death, MI, and stroke as well as TIMI major bleeding

84 in (ASA) reduces the risk of cardiovascular (CV) death, MI, or stroke compared with low-dose aspirin

85 ve way to reduce the risk of cardiovascular (CV) disease, CAHAP remain susceptible to inherited and a

86 Effects of marijuana use on cardiovascular (CV) events and other endpoints were estimated using Kapl

87 The primary outcome was cardiovascular (CV) death, but model performance was also explored for o

88 aim was to determine whether cardiovascular (CV) risk in patients with prostate cancer (PCa) differs

89 ial thromboembolic events (ATEs), comprising CV death, myocardial infarction, ischemic stroke, transi

90 updating of false prior beliefs concerning %CV, reflected in a decreased learning rate of a Rescorla

91 cardiac surgery is indicative of concurrent CV stress rather than an independent renal pathway for l

92 ndependently of the presence of conventional CV risk factors.

93 siveness pattern compared with conventional (CV) mice, and this was dubbed a "hyporesponsive phenotyp

94 The spike count, CV(2), and m-FF of spontaneous activity were also elevat

95 S give three distinct probe approach curves (CV-PACs), which can be used to determine the tip-substra

96 agreement between data on the 2 study days (CV: 7-11%).

97 ted in three consecutive outbreaks to detect CV-A6 and CV-A10, using RT-PCR.

98 t of the presence of traditional and dietary CV risk factors, and compared with high-energy breakfast

99 r and cellular processes that regulate dural CV development in mammals and describe venous malformati

100 ntraction (DE-3 motoneurons) and elongation (CV motoneurons).

101 rst respiratory-related and 342 (4%) a first CV-related hospitalization, and 556 (6%) died.

102 imiting conditions for obtaining and fitting CV-PAC data.

103 2) for ischemic stroke, 1.58 (1.17-2.12) for CV-associated death, 1.08 (0.90-1.29) for MACEs, and 1.0

104 D" model had high discriminatory ability for CV death (c-index 0.81 in derivation cohort, 0.78 in val

105 In recognition of the increasing demand for CV specialists competent in the care of CAHAP, the Ameri

106 Heavy marijuana use is a risk factor for CV disease in HIV-infected men ages 40-60, independent o

107 grees P were independent risk indicators for CV death/MI/iCVA (p < 0.001).

108 t efficacy was assessed by baseline risk for CV death/MI/iCVA, the IMPROVE-IT composite endpoints (CE

109 insult; however, injecting purified Abs from CV animals restored inflammatory responsiveness in GF mi

110 hanistically, injection of serum and Ig from CV mice into GF animals restored IgG deposition, leukocy

111 we discovered that the 3C(pro) proteins from CV-A16, CV-A6, and EV-D68 bind melanoma differentiation-

112 We found that serum transfer from CV naive mice was capable of reversing the inflammatory

113 Admitted patients had a higher general CV risk profile when evaluated with hsTnT, whereas direc

114 ctly discharged patients had a lower general CV risk profile with the same test.

115 rus-induced cryoglobulinemia vasculitis (HCV-CV).

116 ve study of 27 consecutive patients with HCV-CV (median age, 59 y) treated with DAA therapy (21 patie

117 1 on B cells increased in patients with HCV-CV after DAA-based therapy (mean fluorescence units, 37

118 nalyzed blood samples from patients with HCV-CV before and after DAA therapy to determine mechanisms

119 HCV infection without CV, patients with HCV-CV, before DAA therapy, had a lower percentage of CD4+CD

120 spective clinical trial of patients with HCV-CV, DAA-based therapy restored disturbances in periphera

121 In patients with HCV-CV, there was a negative correlation between numbers of

122 and evaluate the use of FFPET for heritable CV disorders via next-generation sequencing.

123 cases with a clinical phenotype of heritable CV disorder were analyzed.

124 Associations of hs-cTnT with incident HF, CV-related mortality, and coronary heart disease were es

125 ysfunction, which may contribute to a higher CV risk.

126 st 1.5 years of follow-up, there were higher CV ischemic events in the orchiectomy group than in the

127 eath, sudden cardiac death, hospitalization, CV hospitalization, and non-CV and nonbleeding-related h

128 otential novel antiviral strategy.IMPORTANCE CV-A16, CV-A6, and EV-D68 are emerging pathogens associa

129 ly for multiple analyses (n = 60) of H2O2 in CV compared to other commercially available electrodes a

130 The ion-specific signals isolated in CV-PACs allow precise and accurate positioning of Hg-bas

131 use expression of arterial-venous markers in CV ECs was not as dramatically affected in Ncx1 (-/-) mu

132 al: 2.9% to 9.7%) absolute risk reduction in CV death/MI/iCVA at 7 years with ezetimibe/simvastatin,

133 minal fold that differs greatly from that in CV-2 vWC, which comprises its BMP-2-binding site.

134 terms and nearby PM2.5 measurements increase CV R(2) by approximately 0.02 and approximately 0.06, re

135 inflammation may contribute to an increased CV risk in PTSD.

136 cells/microL) was associated with increased CV events (OR 4.3; 95% CI, 1.5, 12.9).

137 was independently associated with increased CV events between ages 40-60 after adjusting for age, to

138 ity was highest for postoperative infection (CV = 1.71) and sepsis (CV = 1.37) and among the lowest f

139 ed blood spot in the evaluation of inherited CV disorders.

140 vely, and high reproducibility with interday CVs < 20% for 80% of the glycated peptides.

141 abolites exhibiting a median interlaboratory CV of <20%.

142 icient of variation in interspike intervals (CV(2)) and the trial-to-trial fluctuations in spiking, o

143 subset of 47 children who had received a JE-CV booster after an inactivated JE vaccine primary immun

144 ong-term immune responses induced after a JE-CV booster dose in toddlers were able to neutralize WT v

145 ion) against the homologous strain before JE-CV boost; all were seroprotected up to year 5 after the

146 were seroprotected up to year 5 after the JE-CV boost.

147 uated Japanese encephalitis (JE) vaccine (JE-CV; IMOJEV) induces a protective response in children.

148 imal-to-animal variability in cable lengths (CV = 0.4) and branching patterns in the Gastric Mill (GM

149 October body mass (CV = 2.5%) increased over the study due to higher plant

150 were relatively invariant across sites (mean CV +/- SD = 0.04 +/- 0.01; 7-20 sites in each of 10 neur

151 the (1)H NMR spectroscopic platform (median CV 7.2%).

152 istical quality control measures, the median CV on the original scale for all detected peptides in DB

153 Association between individual or multiple CV risks and MRI outcomes was examined adjusting for age

154 -2)ManalphaOMe (Man3) bound to cyanovirin-N (CV-N) were detected at ambient temperature in aqueous so

155 ccharide ligand, when bound to cyanovirin-N (CV-N), was characterized and revealed that in the comple

156 acterial infection (naive AUC = 0.94; nested CV-AUC = 0.86).

157 hospitalization, CV hospitalization, and non-CV and nonbleeding-related hospitalization, but no incre

158 Diabetes conferred a higher risk of non-CV death, sudden cardiac death, hospitalization, CV hosp

159 en similarities in its associations with non-CV outcomes.

160 attern, the electrophysiological activity of CV motoneurons dominates the cycle.

161 hat this adaptation enhances the capacity of CV-A24v to bind sialic acid.

162 low-up of 3.7 years, there were 591 cases of CV death.

163 ell-encapsulated into PU before a coating of CV was applied (known as PU-AuNPs-CV).

164 simulations indicate that the duty cycle of CV depended on the strength of the positive feedback bet

165 over any sample and enable the deployment of CV-PAS SECM as an analytical tool for traditionally chal

166 Brief excitation of CV motoneurons during crawling episodes resets the rhyth

167 o CV risk, briefly summarize key findings of CV benefit from recent trials, discuss potential mechani

168 prospective cohort of asymptomatic (free of CV events at baseline) adults 40 to 54 years of age.

169 n older patients and those with a history of CV comorbidities within 1.5 years of initiating androgen

170 s, clinical presentations, and mechanisms of CV complications in the MM population.

171 In this study, the membrane potential of CV was manipulated while crawling was monitored through

172 provided a robust tool for the prediction of CV death in patients with stable CHD.

173 against the backdrop of a high prevalence of CV disease in the MM population as well as the adverse c

174 strong graded relationship with the rate of CV death/MI/iCVA, the trial CE, and the individual compo

175 tudy demonstrated a higher incidence rate of CV/CBV events in the omalizumab versus the non-omalizuma

176 izumab-treated patients had a higher rate of CV/CBV serious adverse events (13.4 per 1,000 person yea

177 chiectomy is associated with higher rates of CV ischemic events in older patients and those with a hi

178 (88.9%) had a complete clinical response of CV to DAA therapy at week 24, defined by improvement of

179 The risk of CV death, MI, or stroke in the placebo arm remained roug

180 Both groups had a similar risk of CV ischemic events (ie, MI or IS; hazard ratio, 1.16; 95

181 , use of GnRHa does not increase the risk of CV ischemic events in patients with PCa.

182 The risk of CV-associated death was higher in patients with HS compa

183 d mannoses into the domain A binding site of CV-N than with the nonreducing end unit.

184 increased pathogenicity and rapid spread of CV-A24v.

185 e approach surfaces (CV-PASs), consisting of CVs performed between incremental motor movements.

186 cal assessment and guide management based on CV risk.

187 Analyses included overall CV/CBV events, but focused on the subset of arterial thr

188 licit beliefs, causing them to overestimate %CV.

189 tution that has been adopted by all pandemic CV-A24v strains and we reveal that this adaptation enhan

190 fter sildenafil administration, regional PBV-CV decreased in SS subjects but did not decrease in NS s

191 92-113%, inter-assay 69-138%) and precision (CV<20%).

192 showed linearity (R>0.9995), good precision (CV%<2.78), recovery (91.8-105.1%) and limits of detectio

193 of repeatability and intermediate precision (CV less than 0.25% and 1.7% on average for the retention

194 The precision (CV%) was in the range 10-36% in fresh samples with a tot

195 population with atherothrombosis to predict CV death, myocardial infarction (MI), and ischemic strok

196 gnition that a care team including qualified CV specialists optimizes care delivery for CAHAP.

197 This article reviews the most recent CV outcome trials of the DPP-4 inhibitors (SAVOR-TIMI 53

198 ary considerably in their risk for recurrent CV events.

199 s to improve sympathetic function and reduce CV risk in these patients.

200 ight be embraced by CV specialists to reduce CV events and mortality in their patients.

201 sts liraglutide and semaglutide also reduced CV death and/or major adverse CV events, but did so more

202 empagliflozin, markedly and rapidly reduced CV death and heart failure hospitalization, likely with

203 h recovery (70.8-99.2%), good repeatability (CV<10.4%), high linearity (r>0.9915) and offers practica

204 isfactory repeatability and reproducibility (CV<6%).

205 Part Two will include the sections: CV Medicine & Society, Hypertension, Imaging, Metabolic

206 Part Two includes the sections: CV Medicine & Society, Hypertension, Imaging, Metabolic

207 toperative infection (CV = 1.71) and sepsis (CV = 1.37) and among the lowest for organ transplantatio

208 ted stripping charge extracted from a shared CV-PAS give three distinct probe approach curves (CV-PAC

209 By further linking these three significant CV autoantibodies to the innate and growth factors, we r

210 cold vapour atomic absorption spectroscopy (CV-AAS) and a direct mercury analyser (DMA).

211 ardial infarction (MI), and ischemic stroke (CV death/MI/ischemic cerebrovascular accident [iCVA]).

212 cyclic voltammetry probe approach surfaces (CV-PASs), consisting of CVs performed between incrementa

213 A 10% increase in tacrolimus CV augmented the risk of acute rejection by 20% (adjuste

214 Overall, intrapatient tacrolimus CV was higher in AAs versus non-AAs (39.9 +/- 19.8 % vs

215 tions used to assess intrapatient tacrolimus CV.

216 primary outcome was a composite of long-term CV events or death, which was assessed via national heal

217 on created a discrete crust, indicating that CV electrodes were limited by diffusion.

218 e rhythmic activity of DE-3, indicating that CV feeds back to the rhythmic pattern generator.

219 gnitude of the cycle period, suggesting that CV exerted a positive feedback on the unit(s) of the pat

220 The CV in the R(2)adj also decreased as Nvis increased from

221 The CV(2) was pronounced in amblyopic neurons for high-contr

222 s variable; for Nloc = 100 vs Nloc = 300 the CV in R(2)adj for ultrafine particles decreased from 0.0

223 In addition, the CV-A16, CV-A6, and EV-D68 3C(pro) proteins cleave TAK1 t

224 The Sw for WTW was 0.24 mm and the CV was 1.95%.

225 e protein distribution was calculated as the CV (i.e., SD divided by the mean) of grams of protein pe

226 ke receptor (RLR) pathway was blocked by the CV-A16, CV-A6, and EV-D68 3C(pro) proteins.

227 Our data elucidate the CV-A24v receptor repertoire and point to a role of enhan

228 Furthermore, the CV-A16, CV-A6, and EV-D68 3C(pro) proteins all cleave tr

229 In contrast, flow plays a lesser role in the CV, because expression of arterial-venous markers in CV

230 ants of viral tropism, we set out to map the CV-A24 receptor repertoire and establish whether changes

231 ndicate the potential merit of targeting the CV-A16, CV-A6, and EV-D68 3C(pro) proteins as an antivir

232 Here we demonstrate that the CV-A16, CV-A6, and EV-D68 3C(pro) proteins block MDA5-tr

233 In total, the CV encompasses 15% of CA, 8415 km(2) of which was identi

234 iscuss drug therapy for diabetes relative to CV risk, briefly summarize key findings of CV benefit fr

235 erity and subclinical CVD beyond traditional CV risk and high-sensitivity C-reactive protein.

236 among the lowest for organ transplantation (CV </= 0.43).

237 n the potential range from 0.2 to 1.3V using CV and DPV methods in phosphate buffer solution with pH

238 cific capacitance of 408 F/g at 1 mV/s using CV and 185 F/g at 500 mA/g using charge-discharge measur

239 results achieve an overall cross-validation (CV) R(2) value of 0.80.

240 out-of-sample validation (cross validation, CV).

241 ation about the percentage of cue validity (%CV) was provided in half of the experimental blocks to p

242 ovoltaics), within the Great Central Valley (CV, CA), a globally significant agricultural region wher

243 High tacrolimus variability (CV >40%) was a significant explanatory variable for disp

244 disease, but in 1970 a pathogenic "variant" (CV-A24v) emerged, which is now the main cause of AHC.

245 with less than 10% coefficient of variation (CV) across a range from nearly 27.4 fM to 1.7 pM using t

246 ecision (1.96xSw), coefficient of variation (CV) and intraclass correlation coefficient (ICC).

247 assessed using the coefficient of variation (CV) measured between 1 month posttransplant and the clin

248 s/ml or less and a coefficient of variation (CV) of </=6.1% for each level tested.

249 process replicate coefficient of variation (CV) of <12%.

250 an interlaboratory coefficient of variation (CV) was 7.6%, with 85% of metabolites exhibiting a media

251 rd deviation (SW), coefficient of variation (CV), and intraclass correlation coefficient (ICC).

252 eptides was </=13% coefficient of variation (CV).

253 groups measured as coefficient of variation (CV); and care costs and composite quality indexes.

254 a leaf mass basis (coefficient of variation, CV = 36%) than when expressed on a leaf area basis (CV =

255 o long-term trend (coefficient of variation, CV = 8.8%) and was higher following warm autumn (October

256 justed R(2) (i.e., coefficient of variation, CV) and in regression coefficients among different model

257 and between-batch coefficient of variations (CVs) of present biosensor were 0.18% and 0.32% respectiv

258 the dorsal aorta (DA) and the cardinal vein (CV) in Ncx1 (-/-) mutants, which lack blood flow due to

259 Dural cerebral veins (CV) are required for cerebrospinal fluid reabsorption an

260 s on AP duration (APD), conduction velocity (CV), effective refractory period (ERP), tissue excitatio

261 ntigen were monitored by cyclic voltammetry (CV) and by electrochemical impedance spectroscopy (EIS)

262 Cyclic voltammetry (CV) and differential pulse voltammetry (DPV) studies wer

263 hemistry methods such as cyclic voltammetry (CV) and differential pulse voltammetry (DPV).

264 the drug was measured by cyclic voltammetry (CV) and differential pulse voltammetry (DPV).

265 ctrode was studied using cyclic voltammetry (CV) and electrochemical impedance spectroscopy (EIS).

266 anese dioxide layers via cyclic voltammetry (CV) and electroless deposition (ED).

267 ons was determined using cyclic voltammetry (CV) and scanning electrochemical microscopy (SECM) appro

268 combination of SECM with cyclic voltammetry (CV) at a gold substrate reveals that the electrodepositi

269 s a working electrode in cyclic voltammetry (CV) for the detection of H2O2.

270 Cyclic voltammetry (CV) measurements confirmed the efficiency of the fabrica

271 e spectroscopy (EIS) and cyclic voltammetry (CV) methods.

272 lectrode was assessed by cyclic voltammetry (CV) to determine the surface coverage (Gamma) by CoPc.

273 Cyclic voltammetry (CV) was applied during the WE functionalization process

274 Cyclic voltammetry (CV) was employed to assess the six MnOx nanomaterials, a

275 nt applied potential and cyclic voltammetry (CV) were also investigated.

276 ansform infrared (FTIR), cyclic voltammetry (CV), and electrochemical impedance spectroscopy (EIS).

277 itriptyline sensor using cyclic voltammetry (CV), chronoamperometry (CA) and differential pulse volta

278 the layer, making use of cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS) and sq

279 of techniques including cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS), ellip

280 s) were characterized by cyclic voltammetry (CV), electrochemical impedance spectroscopy (EIS), scann

281 cal techniques including cyclic voltammetry (CV), impedance spectroscopy (EIS) and square wave voltam

282 used to do this work are cyclic voltammetry (CV), linear sweep voltammetry (LSV), chronoamperometry (

283 Electrochemical methods (cyclic voltammetry (CV), potential steps, and electrochemical impedance spec

284 e spectroscopy (EIS) and cyclic voltammetry (CV).

285 e spectroscopy (EIS) and cyclic voltammetry (CV).

286 s characterized by using cyclic voltammetry (CV).

287 e spectroscopy (EIS) and cyclic voltammetry (CV).

288 rGO-PGEs was examined by cyclic voltammetry (CV).

289 se voltammetry (DPV) and cyclic voltammetry (CV).

290 netic information from cyclic voltammograms (CVs) obtained in conditions under which the substrate or

291 ideos of a speaker uttering consonant vowel (CV) syllables /ba/ and /fa/, presented in Auditory-only,

292 ely, our work establishes a paradigm whereby CV malformations result from primary or secondary loss o

293 6 had greater positive rates of 62.33% while CV-A10 had 4.79% in non-EV-A71/CV-A16 HFMD confirmed cas

294 stributed MnO2 throughout the aerogel, while CV deposition created a discrete crust, indicating that

295 hymetric measurements were below 9 mum, with CV of less than 1.6% and ICC of 0.976 or higher.

296 CI, 1.14-1.88], respectively), but not with CV-related hospitalizations or all-cause mortality.

297 robust and reproducible quantification with CVs <15% was possible, however a greater proportion of n

298 he reflectivity simultaneously recorded with CVs show the formation of both Fe2O3 and Fe3O4 oxides.

299 nors and patients with HCV infection without CV, patients with HCV-CV, before DAA therapy, had a lowe

300 nd 12 individuals with HCV infection without CV.